Latest news with #CRSP
Business Insider
30-05-2025
- Business
- Business Insider
Mizuho Securities Reaffirms Their Buy Rating on Crispr Therapeutics AG (CRSP)
In a report released on May 20, Salim Syed from Mizuho Securities maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report), with a price target of $85.00. The company's shares opened today at $37.00. Confident Investing Starts Here: Syed covers the Healthcare sector, focusing on stocks such as Vaxcyte, Wave Life Sciences, and Cytokinetics. According to TipRanks, Syed has an average return of -9.6% and a 35.89% success rate on recommended stocks. Currently, the analyst consensus on Crispr Therapeutics AG is a Moderate Buy with an average price target of $67.63, an 82.78% upside from current levels. In a report released yesterday, Citizens JMP also reiterated a Buy rating on the stock with a $86.00 price target. CRSP market cap is currently $3.39B and has a P/E ratio of -8.19. Based on the recent corporate insider activity of 20 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CRSP in relation to earlier this year. Most recently, in February 2025, John Greene, a Director at CRSP bought 7,000.00 shares for a total of $313,880.00.
Globe and Mail
27-05-2025
- Business
- Globe and Mail
Is the Vanguard Mega Cap Growth ETF Your Ticket to Mega Returns?
The Vanguard Mega Cap Growth ETF (NYSEMKT: MGK) does exactly what its name implies: It buys the largest growth companies. That's been a winning investment plan for a number of years, but investors need to consider the portfolio of this exchange-traded fund (ETF) a bit more deeply before making a new commitment today. Here's why the Vanguard Mega Cap Growth ETF could be a problem for your portfolio if you don't understand what it is you are buying. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » What does the Vanguard Mega Cap Growth ETF do? The Vanguard Mega Cap ETF tracks the CRSP US Mega Cap Growth Index. Some complex math goes into the index, but the outcomes are pretty simple to understand. It uses market caps to determine what stocks count as megacaps. It factors in earnings growth, return on assets, and the investment-to-assets ratio to assign companies to the growth category. The companies that are found in both groups get into the ETF. This isn't a good or bad approach, per se. What it does is put investors into the stocks that are likely to be the most popular during market upturns. That can feel pretty good in a bull market. However, there's a problem to consider because buying the largest, most popular companies is also likely to lead investors to be overweight in a small number of stocks. For example, just three stocks make up more than a third of this Vanguard ETF's portfolio today. All three fall into the technology sector. They are names you likely know: Apple (NASDAQ: AAPL), Microsoft (NASDAQ: MSFT), and Nvidia (NASDAQ: NVDA). But that's not the end of the story, because technology as a sector makes up a huge 60% of the ETF's assets right now. When the market turns lower, the largest and most popular stocks and sectors are likely to lead the way down. Which means that bear markets and corrections are likely to be particularly painful if you own the Vanguard Mega Cap Growth ETF. What has happened in 2025? Which is why it is interesting to consider 2025 as a stress test. Comparing the Vanguard Mega Cap Growth ETF to the broader S&P 500 index (SNPINDEX: ^GSPC) and an equal-weighted version of the S&P 500 index, the Invesco S&P 500 Equal Weight ETF (NYSEMKT: RSP), is illuminating. MGK Total Return Level data by YCharts. Notice that the Vanguard ETF fell furthest during this turbulent period. The more diversified S&P 500 index, which itself leans toward large caps and is market-cap weighted, fell in the middle, performance wise. And the Invesco S&P 500 Equal Weight ETF, which gives each stock in the S&P 500 index the same weighting (meaning that each company has the same opportunity to affect performance), was the best performer. In this period, giving the largest, and likely recently best-performing, companies an overweight status turned into a liability. To be fair, if you look over a longer period of time, the Vanguard ETF is the clear winner. And it rebalances quarterly, so it is fairly quick to change when the market leaders shift. But investors shouldn't go in without understanding the risk that focusing on the biggest and the best can lead to worse drawdowns when the market shifts from a bull to a bear. MGK Total Return Level data by YCharts. There are two big takeaways here There's nothing wrong with buying the Vanguard Mega Cap Growth ETF as long as you understand what it is you own. History suggests that you will do particularly well in good markets. Most investors will see that as a win. That said, you need to go in knowing that downturns could be particularly difficult times for this ETF. And you'll either need to grit your teeth and hold for the long term or, perhaps better, pair the Vanguard Mega Cap ETF with another investment that will perform better during downturns. That way, you have something else to look at besides the red ink the Vanguard Mega Cap Growth ETF is putting up. Should you invest $1,000 in Vanguard World Fund - Vanguard Mega Cap Growth ETF right now? Before you buy stock in Vanguard World Fund - Vanguard Mega Cap Growth ETF, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Vanguard World Fund - Vanguard Mega Cap Growth ETF wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $639,271!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $804,688!* Now, it's worth noting Stock Advisor 's total average return is957% — a market-crushing outperformance compared to167%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of May 19, 2025 Reuben Gregg Brewer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Apple, Microsoft, and Nvidia. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy.
Yahoo
21-05-2025
- Business
- Yahoo
Crispr Therapeutics call volume above normal and directionally bullish
Bullish option flow detected in Crispr Therapeutics (CRSP) with 2,899 calls trading, 1.4x expected, and implied vol increasing almost 2 points to 61.27%. Jun-25 30 calls and Oct-25 40 calls are the most active options, with total volume in those strikes near 910 contracts. The Put/Call Ratio is 0.14. Earnings are expected on August 5th. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on CRSP: Disclaimer & DisclosureReport an Issue Strategic Growth and De-risking: Gil Blum's Buy Rating on Crispr Therapeutics AG Promising Potential of Crispr Therapeutics AG: Buy Rating Backed by Strategic Partnership and Diversified Pipeline Crispr Therapeutics AG: Strategic Advancements and Growth Potential Drive Buy Rating Buy Rating for CRISPR Therapeutics: Strategic Collaboration with Sirius Therapeutics to Enhance Pipeline and Capture Anticoagulant Market Share Strategic Expansion and Promising Ventures Drive Buy Rating for Crispr Therapeutics AG
Yahoo
21-05-2025
- Business
- Yahoo
CRISPR Therapeutics AG (CRSP) Strikes $95M Deal with Sirius to Develop Blood Clot Drug
CRISPR Therapeutics AG (NASDAQ:CRSP) has entered a $95 million upfront partnership with China-based Sirius Therapeutics to co-develop an siRNA drug targeting blood clotting disorders. This marks a strategic shift for CRISPR, traditionally focused on gene editing, recognizing that siRNA's reversible gene silencing offers advantages for some conditions where permanent DNA edits are risky, such as inhibiting factor XI, a clotting protein, where gene editing could cause bleeding complications. A scientist in a laboratory working on a gene editing tool, to create treatments for rare genetic diseases. Under the deal, CRISPR Therapeutics AG (NASDAQ:CRSP) will pay $25 million upfront plus a $70 million equity investment in Sirius. Both companies will share development costs and profits equally, with CRSP handling U.S. commercialization and Sirius covering Greater China. The siRNA drug, SRSD107, showed promising Phase 1 results by reducing factor XI levels up to 95% and is advancing toward a Phase 3 trial by late 2026. CRISPR Therapeutics AG (NASDAQ:CRSP)'s CEO, Samarth Kulkarni, highlighted the complementary nature of siRNA and gene editing, stating siRNA's quicker regulatory path accelerates commercialization compared to gene editing's longer timeline. The company retains excitement about its CRISPR-based cardiovascular programs, including ANGPTL3 and lipoprotein(a) gene edits, but is open to licensing more siRNA assets from Sirius. This diversified approach aims to build a best-in-class cardiovascular franchise by applying the most appropriate technology for each target. Shortly after, Piper Sandler analyst Raghuram Selvaraju maintained an Overweight rating on CRISPR Therapeutics AG (NASDAQ:CRSP) with a $50 price target, citing the Sirius collaboration as a potential near-term revenue catalyst. While we acknowledge the potential of CRSP to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than CRSP and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None. Sign in to access your portfolio
Yahoo
16-05-2025
- Business
- Yahoo
Cathie Wood's ARK Dumps $26 Million Palantir Shares, Bulks Up on Airbnb
May 16 - Cathie Wood's ARK (ARKK) ETFs shifted their bets in the latest trading session. ARK's flagship ARKK ETF snapped up 214,624 shares of Airbnb Inc (NASDAQ:ABNB), spending about $29.6 million on the home-rental platform. Its ARKF ETF added 140,000 shares of eToro Group Ltd (NASDAQ:ETOR) for roughly $7.3 million and scooped up 31,983 shares of CRISPR Therapeutics AG (NASDAQ:CRSP) at a cost of about $1.2 million. On the sell side, ARKK trimmed 206,881 shares of Palantir Technologies Inc (NASDAQ:PLTR), unloading approximately $26.5 million worth of the data-analytics firm. ARKF also pared back UiPath Inc (NYSE:PATH) by 132,149 shares, netting around $1.8 million. ARK's innovation-focused ARKW ETF topped up its GitLab Inc (NASDAQ:GTLB) position with 22,471 shares for $1.2 million. The ETFs made smaller moves in Blade Air Mobility Inc (NASDAQ:BLDE), Nextdoor Holdings Inc (NYSE:KIND) and Twist Bioscience Corp (NASDAQ:TWST), reflecting ARK's strategy to balance high-conviction bets with a broad tech and biotech lineup. These adjustments underscore ARK's willingness to rotate capital toward companies it views as poised for growth, like ABNB and CRSP, while reducing exposure to names where sentiment may have peaked. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
